61240-27-5

Basic information

• Product Name: 2-Propenoic acid, 3-(4-hydroxyphenyl)-, methyl ester, (2Z)-
• CAS NO: 61240-27-5
• Molecular Formula: C10H10O3
• Molecular Weight: 178.188
• Mol File: 61240-27-5.mol
• Article Data: 63

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3-(4-hydroxyphenyl)-, methyl ester, (2Z)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-(4-hydroxyphenyl)-, methyl ester, (2Z)-(61240-27-5)
• EPA Substance Registry System: 2-Propenoic acid, 3-(4-hydroxyphenyl)-, methyl ester, (2Z)-(61240-27-5)

Safety Data

• Hazardous Substances Data: 61240-27-5(Hazardous Substances Data)

Upstream product

• 35047-20-2 2-diazo-3-(4-hydroxyphenyl)propanoic acid methyl ester 
• 107-19-7 propargyl alcohol 
• 292638-85-8 acrylic acid methyl ester 
• 67-56-1 methanol 
• 7400-08-0 p-Coumaric Acid 
• 3650-78-0 methyl (E)-4-bromocinnamate 
• 501-98-4 (Z)-p-coumaric acid 
• 1426417-47-1 1,5-di-O-cis-p-coumaroylquinic acid 
• 1426417-45-9 1-O-trans-p-coumaroyl-5-O-cis-p-coumaroylquinic acid 
• 1104327-81-2 cyanidin 3-O-[2-O-(β-xylopyranosyl)-6-O-((Z)-p-coumaroyl)-β-galactopyranoside] 
• 123-08-0 4-hydroxy-benzaldehyde 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 3943-97-3 methyl 4-hydroxycinnamate 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 3843-74-1 methyl 3,4-dihydroxycinnamate 
• 3943-97-3 methyl 4-hydroxycinnamate 
• 55226-78-3 methyl (2E)-3-[4-(acetyloxy)phenyl]-2-propenoate 
• 501-98-4 (Z)-p-coumaric acid 
• 7400-08-0 para-coumaric acid 
• 19310-29-3 3-(4-methoxyphenyl)acrylic acid methyl ester 
• 81609-52-1 methyl 4-hexyloxy-cinnamate 
• 1287677-55-7 C₂₁H₂₅NO₃ 
• 1287677-54-6 C₁₈H₁₈O₂ 
• 126269-86-1 C₂₅H₃₄O₃ 
• 6466-92-8 methyl O-geranyl-4-coumarate 
• 866417-47-2 methyl {4'-[3''-(methyl prop-2''(E)-enoate)]phenyl 2,3,4-tri-O-acetyl-β-D-glucopyranosid}uronate 
• 100798-34-3 3-(4-methoxycarbonylmethoxy-phenyl)acrylic acid methyl ester 

Relevant articles and documents

Synthesis and Evaluation of PPARδAgonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis

We synthesized a directed library of compounds to explore the structure-activity relationships of peroxisome proliferator-activated receptor δ(PPARδ) activation relative to mesenchymal stem cell (MSC) osteogenesis. Our scaffold used para-substituted cinnamic acids as a polar headgroup, a heteroatom and heterocycle core connecting units, and substituted phenyl groups for the lipophilic tail. Compounds were screened for their ability to increase osteogenesis in MSCs, and the most promising were examined for subunit specificity using a quantitative PPAR transactivation assay. Six compounds were selected for in vivo studies in an ovariectomized mouse model of human postmenopausal osteoporosis. Four compounds improved bone density in vivo, with two (12d and 31a) having activity comparable to that of GW0742, a well-studied PPARδ-selective agonist. 31a (2-methyl-4-[N-methyl-N-[5-methylene-4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]]aminocinnamic acid) had the highest selectivity for PPARδcompared to other subtypes, its selectivity far exceeding that of GW0742. Our results confirm that PPARδis a new drug target for possible treatment of osteoporosis via in situ manipulation of MSCs.

BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA

The present invention relates to divalent compounds binding to LecA. The compounds are useful to block biofilm formation of Pseudomonas aeruginosa. The invention further relates to pharmaceutical compositions comprising these compounds and to therapeutic methods and uses of these compounds, in particular to therapeutic methods and uses for the treatment of Pseudomonas aeruginosa infections in a subject. The invention also relates to imaging of infections, such as biofilms produced by Pseudomonas aeruginosa, by using these divalent compounds.

Preparation method of esmolol hydrochloride intermediate

The invention belongs to the field of organic synthesis of medicines, and particularly relates to a preparation method of a medicine esmolol hydrochloride intermediate for treating hypertension. The synthesis route provided by the invention comprises the following steps: reacting p-bromophenol with methyl acrylate in the presence of a palladium catalyst and a phosphine ligand to generate 3-(4-hydroxyphenyl) methyl acrylate; and hydrogenating the generated 3-(4-hydroxyphenyl) methyl acrylate in the presence of a palladium-carbon catalyst to obtain a target product methyl 4-hydroxyphenylpropionate. The method has the advantages of short reaction steps, cheap and accessible raw materials, simple technique and convenience of operation, and does not need special reaction conditions, thereby being more suitable for industrial production.